相关实验视频

Updated: Sep 13, 2025

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Published on: February 6, 2017

通过神秘的抗原来照亮癌症治疗

Jiling Feng¹, Yu Zeng¹, Shengli Li¹

¹Precision Research Center for Refractory Diseases, Shanghai Jiao Tong University Pioneer Research Institute for Molecular and Cell Therapies, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201620, China.

Trends in cancer

|July 26, 2025

概括

研究人员在胰腺癌中发现了独特的癌症. 这些非正规的HLA-可以通过T细胞受体作为潜在的胰腺癌免疫治疗的目标.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
基因组学就是基因组学.

背景情况:

胰腺癌,特别是胰腺管腺癌 (PDAC),仍然是瘤学的重大挑战.
识别特定的瘤抗原对于开发有效的免疫疗法至关重要.
由于抗原异质性,目前的免疫疗法经常难以向PDAC等固体瘤.

研究的目的:

为了识别新型的,免疫性受限于胰腺癌.
探索这些非正规的HLA- (ncHLAp) 作为T细胞治疗的点的潜力.
为了验证能够识别PDAC特异性抗原的T细胞受体 (TCR).

主要方法:

利用基于翻译的过策略来分析基因组和蛋白质组数据.
已识别的非正规的HLA-I结合 (ncHLAp) 来自未注释的开放阅读框架 (ORF).
验证的抗原特异性T细胞受体 (TCRs) 在临床前模型中准PDAC.

主要成果:

在胰腺癌中发现了免疫性,癌症受限的非正规HLA-I结合 (ncHLAp).
从以前未被注释的ORF产生的未发现的神秘抗原.
在临床前设置中专门针对胰腺管腺癌 (PDAC) 的验证的TCR.

结论:

非正规的HLA是PDAC新型癌症抗原的有希望的来源.
通过验证的TCR来准这些ncHLAp,为胰腺癌免疫治疗提供了一个潜在的新策略.
这项研究为开发针对胰腺癌的有效免疫疗法开辟了新的途径.

关键词:

T细胞的识别功能隐秘的类.非正规的HLA-I结合.胰腺癌是一种癌症.

更多相关视频

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...